|
05 Aug 2021
|
Windlas Biotech
|
Prabhudas Lilladhar
|
994.25
|
|
|
|
IPO Note
|
|
|
experience in manufacturing (solid/ liquid) multiple dosage offers a comprehensive range of CDMO services in India. Over time Windlas evolved and 6) strong financial performance with experienced management. It owns...
|
|
04 Aug 2021
|
Windlas Biotech
|
Ashika Research
|
994.25
|
|
|
|
IPO Note
|
|
|
5 each, (Comprising of fresh issue of 3,586,957 Equity Shares* (Rs. 165 cr.) and Offer for Sale of 5,142,067 Equity Shares (Rs. 236.5 cr.*) by Selling Shareholder)....
|
|
03 Aug 2021
|
Windlas Biotech
|
ICICI Securities Limited
|
994.25
|
|
|
|
IPO Note
|
|
|
Leading player in fast growing CDMO market With increasing globalisation and focus of large pharmaceutical players on cutting costs and optimising operations, CDMOs have seen significant acceptance in the pharmaceutical industry internationally over the last few years. The domestic formulations CDMO market has grown at a higher rate of ~13% compared to ~8.6% growth of the domestic formulations market (in terms of consumption) in the past five years. The company believe this increasing use of outsourcing by pharmaceutical companies for launch of...
|
|
03 Aug 2021
|
Windlas Biotech
|
Angel Broking
|
994.25
|
|
|
|
IPO Subscribe
|
|
|
Windlas Biotech Ltd. The company was incorporated in 2001 based in Dehradun. The Company operating with 3 business verticals 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market 3. Exports. The company currently owns and operates four manufacturing facilities located at Dehradun in Uttarakhand. As of March 31, 2021, their
|